Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers


  Drug Resistance

  Free Subscription

Articles published in Antivir Ther

Retrieve available abstracts of 20 articles:
HTML format

Single Articles

    March 2019
  1. YOUNGER J, Raboud J, Szadkowski L, Harrigan R, et al
    Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP.
    Antivir Ther. 2019 Mar 15. doi: 10.3851/IMP3302.
    PubMed     Abstract available

    February 2019
  2. HUNT GM, Ledwaba J, Kalimashe M, Salimo A, et al
    Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods.
    Antivir Ther. 2019 Feb 11. doi: 10.3851/IMP3294.
    PubMed     Abstract available

    October 2018
  3. FERRARI D, Spagnuolo V, Manca M, Bigoloni A, et al
    Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients.
    Antivir Ther. 2018 Oct 24. doi: 10.3851/IMP3275.
    PubMed     Abstract available

    January 2018
  4. PETERS L, Mocroft A, Grint D, Moreno S, et al
    Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.
    Antivir Ther. 2018 Jan 5. doi: 10.3851/IMP3218.
    PubMed     Abstract available

    November 2017
  5. JIA J, Tang H, Ning Q, Jiang J, et al
    Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.
    Antivir Ther. 2017 Nov 8. doi: 10.3851.
    PubMed     Abstract available

    October 2017
  6. HOPPE A, Giuliano M, Lugemwa A, Thompson JA, et al
    HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
    Antivir Ther. 2017 Oct 11. doi: 10.3851/IMP3200.
    PubMed     Abstract available

    April 2017
  7. LEE SH, Cheon GJ, Kim HS, Kim SG, et al
    Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicenter trial.
    Antivir Ther. 2017 Apr 24. doi: 10.3851/IMP3169.
    PubMed     Abstract available

    February 2017
  8. BISSIO E, Barbas MG, Kademian S, Bouzas MB, et al
    Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.
    Antivir Ther. 2017 Feb 24. doi: 10.3851/IMP3147.
    PubMed     Abstract available

  9. KREUTZWISER D, Sheehan N, Dayneka N, Lemire B, et al
    Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV.
    Antivir Ther. 2017 Feb 15. doi: 10.3851/IMP3139.
    PubMed     Abstract available

    January 2017
  10. PORTER DP, Kulkarni R, Garner W, Miller MD, et al
    Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/ tenofovir DF or efavirenz/emtricitabine/ tenofovir DF through 96 weeks.
    Antivir Ther. 2017 Jan 16. doi: 10.3851/IMP3128.
    PubMed     Abstract available

  11. MARGOT N, Cox S, Das M, McCallister S, et al
    Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide or elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Antivir Ther. 2017 Jan 11. doi: 10.3851/IMP3125.
    PubMed     Abstract available

  12. SIMONETTI FR, Cattaneo D, Zanchetta N, Giacomet V, et al
    Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for TDM.
    Antivir Ther. 2017 Jan 4. doi: 10.3851/IMP3122.
    PubMed     Abstract available

  13. DONG H, Zhou B, Kang H, Jin W, et al
    Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients.
    Antivir Ther. 2017;22:43-51.
    PubMed     Abstract available

    November 2016
  14. GILL VC, Lynch T, Ramazani S, Krentz HB, et al
    Reporting on the prevalence of antiretroviral drug resistance in a regional HIV population over 20 years: a word of caution.
    Antivir Ther. 2016 Nov 2. doi: 10.3851/IMP3105.
    PubMed     Abstract available

    September 2016
  15. CAPETTI AF, Orofino G, Sterrantino G, Cossu MV, et al
    Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
    Antivir Ther. 2016 Sep 23. doi: 10.3851/IMP3095.
    PubMed     Abstract available

    June 2016
  16. BELYHUN Y, Maier M, Liebert UG
    HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
    Antivir Ther. 2016 Jun 29. doi: 10.3851/IMP3060.
    PubMed     Abstract available

    May 2016
  17. ARCHAMPONG TN, Boyce CL, Lartey M, Sagoe KW, et al
    HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
    Antivir Ther. 2016 May 11. doi: 10.3851/IMP3055.
    PubMed     Abstract available

    March 2016
  18. MIKULA JM, Manion MM, Maldarelli F, Suarez LM, et al
    Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir DF-associated renal tubulopathy.
    Antivir Ther. 2016 Mar 8. doi: 10.3851/IMP3040.
    PubMed     Abstract available

    November 2015
  19. TAMBUYZER L, Thys K, Hoogstoel A, Nijs S, et al
    Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
    Antivir Ther. 2015 Nov 13. doi: 10.3851/IMP3011.
    PubMed     Abstract available

  20. NDAHIMANA JD, Riedel DJ, Muhayimpundu R, Nsanzimana S, et al
    HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda.
    Antivir Ther. 2015 Nov 12. doi: 10.3851/IMP3005.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.